We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.
- Authors
Opalinska, Marta; Lezaic, Luka; Decristoforo, Clemens; Kolenc, Petra; Mikolajczak, Renata; Studen, Andrej; Simoncic, Urban; Virgolini, Irene; Trofimiuk-Muldner, Malgorzata; Garnuszek, Piotr; Rangger, Christine; Fani, Melpomeni; Glowa, Boguslaw; Skorkiewicz, Konrad; Hubalewska-Dydejczyk, Alicja
- Abstract
Gallium-68-labelled somatostatin analogues are a gold standard of neuroendocrine tumors (NETs) PET imaging being a tool for personalized treatment. SPECT radiopharmaceuticals represent the cornerstone of molecular imaging due to their wide availability [[2]] and the development of a radiopharmaceutical based on technetium-99 m-labeled SSTR antagonist would improve access to such clinically feasible diagnostic tool. Long-acting somatostatin analogue was withdrawn 4 weeks before imaging Although PET is considered more sensitive than SPECT [[4]], the presented new radiopharmaceutical holds promise to provide higher TBR values compared to the current gold standard SP 68 sp Ga-DOTA-TATE PET/CT.
- Subjects
NEUROENDOCRINE tumors; SOMATOSTATIN; SOMATOSTATIN receptors; POSITRON emission tomography; SPORTS sciences
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2023, Vol 50, Issue 13, p4110
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-023-06335-9